Executive Summary
Sole NASA contract is a neutral $109M delivery order to nonprofit Caltech (JPL operator) for space R&D including EMIT project, with $90M outlayed and $16M options unexercised through 2028. Limited direct equity implications due to recipient's tax-exempt status, but affirms steady NASA commitment to FFRDC operations. Investors should monitor task orders and options for indirect space sector stability signals.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior All NASA Contracts digest from March 14, 2026.
Investment Signals (2)
- Unexercised Options Potential (MEDIUM)▲
$16M options could lift ceiling to $125M upon NASA exercise.
- Task Order Dependence (HIGH)▲
Full $109M obligation relies on future NASA task orders through 2028.
Risk Flags (1)
- Execution [MEDIUM RISK]▼
Long 10-year period to 2028 with obligation tied to NASA task orders.
Opportunities (1)
- ◆
Continued JPL FFRDC role enables additional NASA task orders post-2028.
Sector Themes (1)
- ◆
Concentration in single large non-competed order to Caltech/JPL highlights sustained funding for space science R&D.
Watch List (1)
- 👁
{"entity"=>"Caltech/JPL", "reason"=>"$109M obligation with $16M options signals potential for scaled NASA R&D funding.", "trigger"=>"Option exercises or new task orders exceeding $10M"}
Get daily alerts with 2 investment signals, 1 risk alerts, 1 opportunities and full AI analysis of all 1 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: All NASA Contracts
🇺🇸 More from United States
View all →May 27, 2026
US Pre-Market SEC Filings Roundup — May 27, 2026
US Pre-Market SEC Filings Roundup
May 27, 2026
S&P 500 Technology Sector SEC Filings — May 27, 2026
S&P 500 Technology Sector SEC Filings
May 27, 2026
Orphan Drug Approvals — May 27, 2026
Orphan Drug Approvals
May 27, 2026
Big Pharma Approvals — May 27, 2026
Big Pharma Approvals